Efficient immunomagnetic isolation of melanoma cells with diverse genetic backgrounds from blood


Melanoma is a highly aggressive cancer and until recently, the majority of patients with visceral metastases had survival rates of less than one year. 

Targeted treatment has revolutionized melanoma therapy with BRAF and MEK inhibitors tailored to BRAF mutant melanomas producing remarkable responses until resistance, caused by various mechanisms, occurs. 

The potential use of circulating tumor cells (CTCs) in melanoma to derive tumor bioinformation for such targeted treatment and importantly monitor these cells for emerging resistance biomarkers requires effective strategies of melanoma CTC isolation, however melanoma tissues display high intra- and inter-patient heterogeneity, which also affects cell surface protein expression.